David Sidransky, a director at Champions Oncology, Inc., has exercised stock options to purchase 31,216 shares of common stock at a price of $4.76 each. This transaction occurred on November 5, 2026, and was reported in a recent SEC filing.

This move is significant as it reflects Sidransky's confidence in the company's future prospects. Champions Oncology operates in the biological products sector, which is critical for the development of innovative therapies and treatments. The exercise of these options may also influence other directors and executives within the industry.

Background

Champions Oncology, Inc. is a company focused on providing solutions to personalize cancer treatment. The company is classified under the SIC code for Biological Products (No Diagnostic Substances) [2836]. Its headquarters is located at 855 N. Wolfe Street, Suite 619, Baltimore, MD. The company, incorporated in Delaware, has a fiscal year ending on April 30.

What the Filing Says

The SEC filing indicates that Sidransky acquired the shares through an option to purchase common stock. The transaction code listed is "A," indicating that it was an acquisition. The filing notes, "The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027, and August 5, 2027, respectively." Following this transaction, Sidransky owns 31,216 shares of the company.

Impact

This transaction may affect various stakeholders, including investors, employees, and competitors in the life sciences sector. As a director, Sidransky's actions could influence perceptions of the company's stability and growth potential. Other directors and executives may also feel encouraged to follow suit, potentially impacting stock performance and investor confidence.

What's Next

The filing does not say what happens next.